Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine
LC Villaruz, MA Socinski, J Weiss - Frontiers in Oncology, 2023 - frontiersin.org
Major advances in the diagnosis and treatment of non-small cell lung cancer (NSCLC) have
resulted in a sharp decline in associated mortality rates, thereby propelling NSCLC to the …
resulted in a sharp decline in associated mortality rates, thereby propelling NSCLC to the …
[HTML][HTML] Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications
C Parisi, M Tagliamento, L Belcaid, M Aldea… - The Journal of Liquid …, 2023 - Elsevier
Tumor derived biomarkers including circulating tumor DNA (ctDNA) and/or circulating
tumors cells (CTCs) may be detected and quantified through liquid biopsy (LB). ctDNA …
tumors cells (CTCs) may be detected and quantified through liquid biopsy (LB). ctDNA …
The use of liquid biopsy in the molecular analysis of plasma compared to the tumour tissue from a patient with brain metastasis: a case report
V Aran, VM Zogbi, RL Miranda, F Andreiuolo… - Medicina, 2023 - mdpi.com
Different cancers have multiple genetic mutations, which vary depending on the affected
tumour tissue. Small biopsies may not always represent all the genetic landscape of the …
tumour tissue. Small biopsies may not always represent all the genetic landscape of the …
Comparative study on the mutation spectrum of L‐MYC and C‐MYC genes of blood cfDNA in patients with ovarian cancer and healthy females
S Shabir, A Asiaf - Journal of Obstetrics and Gynaecology …, 2023 - Wiley Online Library
Background This study aimed at detecting the mutations of L‐MYC and C‐MYC genes in
ovarian cancer (OC) patients and healthy female volunteers using cell‐free DNA (cfDNA) …
ovarian cancer (OC) patients and healthy female volunteers using cell‐free DNA (cfDNA) …
Biomarker Testing for Guiding Precision Medicine for Patients with Non-Small Cell Lung Cancer
AH Fox, M Alexander, JA Forcucci, GA Silvestri - Chest, 2024 - Elsevier
The initial management of patients with lung cancer is growing more complex in the context
of an expanding number of precision medicine treatments. These challenges are …
of an expanding number of precision medicine treatments. These challenges are …
[HTML][HTML] Matched tissue and liquid biopsies for advanced non-small cell lung cancer patients A potentially indispensable complementary approach
P Hofman - Translational Oncology, 2023 - Elsevier
The introduction of liquid biopsies (LB) has brought forth a number of therapeutic
opportunities into the domain of thoracic oncology. Many of which have been adopted for …
opportunities into the domain of thoracic oncology. Many of which have been adopted for …
Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
J Peng, S Fang, M Li, Y Liu, X Liang, Z Li… - Open Life …, 2023 - degruyter.com
The aim of this study is to investigate certain genetic features of intrahepatic
cholangiocarcinoma (ICCA). A total of 12 eligible ICCA patients were enrolled, and tumor …
cholangiocarcinoma (ICCA). A total of 12 eligible ICCA patients were enrolled, and tumor …